BS-006
AXP000090.1 · Oncolytic virus
- Platform
- HSV-2 (strain HG52, ICP34.5- ICP47-)
- Originator
- Binhui Biopharmaceutical
- Sponsor
- Binhui Biopharmaceutical
Names
| Name | Type | Source |
|---|---|---|
| BS-006 | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 2 (NCBI Taxonomy 10310)
- Strain
- HG52
- Replication
- conditionally replicating
- Modifications
- ICP34.5 and ICP47 deleted
- Transgenes
- anti-PD-L1/CD3 bispecific antibody
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C188176
Approvals
No regulatory approval recorded.
Clinical trials (3)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05938296 | oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection | Suspended | Phase 1 | 2023-12-19 | 2026-12-19 | 29 | Solid Tumor |
| NCT07382531 | OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors | Recruiting | Phase 1/2 | 2023-09-07 | 2027-12-31 | 30 | Solid Tumor |
| NCT05393440 | First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer | Unknown | Phase 1 | 2022-09-16 | 2023-12-31 | 18 | Uterine Cervical Neoplasms |
Recent changes
No changes recorded in its trials yet.
Notes
OH2 backbone armed with an anti-PD-L1/CD3 bispecific antibody instead of GM-CSF. A first-in-human phase I in cervical cancer is registered; dosing not confirmed from a primary report.
How to cite
BS-006 (AXP000090.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000090.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.